shuinu9870 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： shuinu9870 更多一手调研纪要和研报数据加V： 27 Nov 2024 05:21:48 ET │ 10 pages China Hardware China Smartphone Oct Sell-in Shipments -1% YoY (+18% MoM) shuinu9870 CITI'S TAKE Per CAICT, China smartphone sell-in shipments declined 1% YoY to 27.9mn in Oct-24 (vs. -26% YoY in Sep-24), bringing YTD shipments to 234mn (+6% YoY) vs. sell-out of +2%. We noted sequential improvemen ...

shuinu9870 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： Technology shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： Asia Pacific Equity Research 27 November 2024 J P M O R G A N This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redi ...

shuinu9870 shuinu9870 shuinu9870 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多一手调研纪要和研报数据加V： 更多资料加入知识星球：水木调研纪要 关注公众号：水木纪要 shuinu9870 Neutral Price (26 Nov 24 16:10) HK$77.05 Target price HK$70.80 Expected share price return -8.1% Expected dividend yield 4.1% Expected total return -4.0% Market Cap HK$217,992M US$28,009M 更多一手调研纪要和研报数据加V： shuinu9870 更多一手调研纪要和研报数据加V： 26 Nov 2024 21:58:11 ET │ 11 pages Anta Sports Products (2020.HK) Issue of €1.5bn of new 5-year zero-coupon CBs, albeit Rmb32bn+ of net cash shuinu9870 CIT ...

欢迎加入会议请输入参会密码并用警号解决您已成功加入会议欢迎参加本次会议会议即将开始请稍候 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后 感谢大家参加本次会议会议即将开始请稍后感谢大家参加本次会议会议即将开始 感谢大家参加本次会议会议即将开始请稍后 The meeting ...

的权利市场有风险投资趋紧振各位投资者大家早上好欢迎收看我们本周的周四早盘测我是华盛顿交易吴非凡今天我们汇报的主要内容还是重点强调一下我们继续在交易环境当中建议重点聚焦在内需生收器方向主要是 呃这个三个内容一是这个航空第二呢顺风第三呢这个内贸捷运那这是我们最近重点关注的这个三个这个方向那首先对于航空因为航空是这个经典顺周期的这样一个品种而是内顺周期品种那这个近期整个市场表现当中大家关注也比较多那这也是我们在这个年度策略当中那第一个放在场面就是这个航空那为什么那我觉得是有几个因素在近期他走强有几个因素包括在所有内需顺周期方向当中 航空在近期的表现应该说是这个耗钱的那首先丁老师认为就是接下来要过特别关注的那应该市场比较关注12月份那整个接下来这个中央的这个经费当中那整个的一些这个表述那包括财政是否能发力那继续的发力因为我们是已经是这个一揽子的政策那不断在路上那从历史上经验来看的话就我们之前发过报告就是关于这个08到10年整个经验 那08-10那在我们这个一揽子的这个经济实习计划之后应该说我们觉得是看到一个现象和特征就他对整个实体的这个传导大概需要这个两到三个月的时间但对于航空他是一个及时反应因为对航空的这个首先我们 ...

Summary of Conference Call Notes Industry Overview - The discussion primarily revolves around the **liquid cooling industry** and its integration with **GPU** and **CPU** technologies, highlighting the roles of major players like **NVIDIA** and **Huawei** in the market [1][2]. Key Players and Their Roles - **NVIDIA** is set to launch its first official liquid cooling product, the **GV200**, which is expected to significantly increase shipments in the coming year [1]. - **Huawei** has been more proactive in liquid cooling solutions, having introduced its first solution in 2020 and actively collaborating with partners for further development [1]. - **Intel** plays a crucial role in promoting standardization within the liquid cooling supply chain, addressing compatibility issues that currently hinder the industry [2]. Market Demand and Segmentation - The demand for chips can be segmented into two main categories: **telecom operators** and large internet companies like **ByteDance**. The telecom sector has shown strong demand, as evidenced by the release of a liquid cooling white paper in 2022 [3]. - Internet giants are also increasingly adopting liquid cooling in their general servers, indicating a growing trend in the industry [4]. Investment Opportunities - Companies that align with the three key players—**Huawei**, **telecom operators**, and proactive internet companies—are likely to see better performance and investment returns [5]. - Domestic **IDC** firms are expanding into Southeast Asia, presenting additional opportunities for local cooling solution providers [6]. Technology and Market Trends - The liquid cooling technology is still in its early stages, providing new opportunities for domestic manufacturers to enter the market, especially as traditional air cooling solutions are more established [7]. - The **liquid cooling plate** segment is highlighted as a significant area for investment, accounting for approximately **30%** of the total cooling solution market, with a stable long-term growth outlook [8]. - The **CDU and manifold** segments are expected to show clear performance improvements in 2024, particularly for leading domestic players [9]. Future Outlook - The period from **2022 to 2024** is viewed as a critical phase for the liquid cooling industry, transitioning from initial development to broader market adoption [10]. - Companies with strong relationships with telecom operators and proactive internet firms are positioned to achieve better performance [11]. - The Southeast Asian market is identified as a key area for expansion, with potential long-term opportunities in the U.S. market as well [11]. Conclusion - The conference call emphasizes the importance of collaboration among key industry players and the potential for growth in the liquid cooling market, particularly as new technologies are adopted and standardized [12].

expanded edition Prices may vary in areas outside metropolitan Washington. a haLf-cENTURY Of GEORGE f. WILL Celebrating the 'Iron Man' of op-ed columnists. SPEcIaL SEcTION faITh IN a WaRMING WORLd How climate change is affecting religious rituals. SPEcIaL SEcTION INSPIREd LIfE Stories of humanity to lift your holiday spirits. a14-16 ABCDERE V1 V2 V3 V4 | --- | --- | --- ...

Summary of Key Points from the Conference Call Industry or Company Involved - The conference call primarily discusses the **healthcare industry**, specifically focusing on **Medicare and Medicaid** policies regarding obesity drugs and the implications of potential changes under the Biden administration. Core Points and Arguments 1. **Expansion of Coverage for Obesity Drugs** The Biden administration is proposing that Medicare and Medicaid cover popular obesity drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound for individuals who are obese, regardless of whether they have other diseases such as diabetes. This change could extend coverage to approximately **3.4 million Americans** on Medicare and an additional **4 million** on Medicaid [31][32][34]. 2. **Financial Implications** The proposed coverage expansion could lead to tens of billions of dollars in additional costs for Medicare and Medicaid, as these drugs can list for over **$1,000 per month**. Covering treatment for just **10% of Medicare patients** who could qualify for these medications could cost more than **$26 billion annually**, which represents about **20% of Medicare's annual drug spending** [31][32]. 3. **Political Challenges** The proposal faces uncertain prospects as it would need to be finalized by the incoming Trump administration, which has indicated a desire to cut federal spending. This creates a political dilemma for Trump's health officials, who must decide whether to implement an expensive plan that is popular with some constituents or to cancel it [31][32]. 4. **Market Potential for Obesity Drugs** The obesity-drug market, currently dominated by Eli Lilly and Novo Nordisk, is projected to potentially exceed **$100 billion in annual sales** globally. Amgen's obesity-drug candidate, MariTide, has shown promising results in midstage studies, with patients losing **20% of their body weight** compared to those on placebos. Analysts expect Amgen could capture **10% to 15%** of this market [35]. 5. **Regulatory Context** The current law governing Medicare's prescription-drug benefit excludes weight-loss drugs, as they were historically viewed as cosmetic treatments. The Biden administration's proposal aims to classify these medications as treatments for the disease of obesity, which could allow for coverage despite existing prohibitions [32][34]. Other Important but Possibly Overlooked Content 1. **Impact on Drug Pricing** The wide variation in drug prices across different Medicare plans complicates the landscape for patients. For example, the same drug can have prices that differ by thousands of dollars depending on the plan and region, leading to significant out-of-pocket costs for patients [33]. 2. **Public Health Perspectives** Some public health leaders express hope that the proposed changes could strengthen the NIH and improve access to obesity treatments, while others caution against the reliance on pharmaceutical solutions over promoting healthy lifestyle changes [27][32]. 3. **Future of Drug Development** The ongoing development of new obesity drugs, such as Amgen's MariTide, highlights the competitive landscape in the pharmaceutical industry, with significant investments and research aimed at addressing obesity as a major public health issue [35]. This summary encapsulates the key discussions and implications surrounding the proposed changes to Medicare and Medicaid drug coverage, particularly in the context of obesity treatments and the broader healthcare landscape.

证券研究报告·行业深度·2025 年投资策略报告 REITs2025 年投资策略报告：关注政策 及利率共振，首推消费等抗周期业态 核心观点 REITs 市场迈入常态化发行新阶段，一级审核提速；二级市场 2024 年经历三轮上涨，均有资金面及政策面双重共振驱动。展望后市， 常态化发行将继续支撑市场提质扩容， 2025 年底 C-REITs 市场 规模有望达 85 只、2450 亿元，在数量上仅次于美国；二级市场 方面预计年末延续震荡横盘，明年走势需关注政策出台节奏和利 率走势；增量政策仍有可为，监管中长期有望从专项立法、引入 增量资金、加强主动管理等方面推动 REITs 市场高质量发展。我 们认为当前 REITs 投资，一级市场估值审慎，对于二级溢价较高 且具备抗周期属性的业态，如市政环保、保租、能源、厂房等值 得重点关注；二级市场首推消费业态，保租房及厂房可择机逢低 布局，并建议优选板块内高股息、强原权标的。 摘要 feijinglun@csc.com.cn 18518691700feijinglun@csc.com.cn 18518691700 一级发行常态化审核提速，二级三轮上涨行情均因政策及资金面 因素 ...

Investment Rating - The report does not explicitly provide an investment rating for the industry or company discussed. Core Insights - HSBC Private Wealth Planning is a strategic focus for the group, established in 2020, with significant investment aimed at capturing the growing wealth management demand in China due to the expanding middle class [2][3] - The company has expanded its presence in major Chinese cities, indicating a strong commitment to the market [2] - A high percentage of clients (87%) view HSBC Private Wealth Planning as a key brand for wealth management, with 82% rating their satisfaction highly [3] Summary by Sections Company Overview - HSBC Private Wealth Planning was founded in 2020 and has received substantial investment from the group, highlighting its importance within the organization [2] - The company has established branches in multiple cities including Shanghai, Guangzhou, and Beijing, reflecting its growth strategy in China [2] Market Position - The report emphasizes the significant demand for wealth management services in China, driven by the rapid economic development and the increasing number of affluent individuals [2][3] - HSBC's historical presence in China dates back to the Qing Dynasty, which adds to its credibility and brand recognition in the market [3] Client Satisfaction - The report notes that a large majority of clients express high satisfaction with HSBC's services, indicating a strong market position and client loyalty [3] - The company's recent slogan, "We understand what you care about, providing you peace of mind," reflects its commitment to client-centric services [3]